Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SEATTLE—Steven C. Quay, President and CEO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), recently acquired 11,239 shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a weighted average price of $0.8797 per share, with transaction prices ranging from $0.8794 to $0.9100, resulting in a total transaction value of $9,886. The purchase price sits near the current trading level of $0.87, with the stock down about 43% over the past year.
Following this transaction, Quay directly owns 13,898 shares of Atossa Therapeutics. Additionally, he holds indirect ownership of 22,254 shares through Ensisheim Partners, LLC, a company co-owned with Dr. Shu-Chih Chen. Quay and Dr. Chen share voting and investment power over these securities, although Quay disclaims beneficial ownership except for his financial interest.
This purchase reflects Quay’s continued investment in Atossa Therapeutics, a Seattle-based biopharmaceutical company focused on oncology and infectious disease treatments.
In other recent news, Atossa Therapeutics announced its fourth-quarter 2024 earnings, reporting an earnings per share (EPS) of -0.04, which exceeded the forecasted -0.065. This result indicates a better-than-expected financial performance, despite the negative EPS. The company also highlighted a significant decrease in operating expenses from 2023, which contributed to a reduced net loss of $25.5 million. Atossa Therapeutics has been granted a new patent for its breast cancer treatment formulations, specifically for its (Z)-endoxifen drug, further strengthening its intellectual property portfolio. The company is advancing its clinical programs, including a Phase 3 trial for breast cancer prevention, aiming to reduce interval breast cancer in high-risk women. H.C. Wainwright maintained its Buy rating and a $7.00 price target for Atossa, citing the strategic focus on Z-endoxifen’s development for metastatic breast cancer. Atossa’s CEO expressed confidence in the potential of (Z)-endoxifen to address unmet needs in breast cancer treatment, emphasizing ongoing efforts to secure FDA approval. These developments reflect Atossa’s commitment to innovation and strategic growth in the breast cancer treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.